Climb Bio (CLYM) TD Cowen 45th Annual Healthcare Conference summary

Corporate strategy and funding

• Focused on developing therapies for immune-mediated diseases with growing global prevalence.

• Two main programs: anti-CD19 monoclonal antibody (Budoprutug) and anti-APRIL monoclonal antibody (CLYM116).

• Well-funded through 2027, supporting multiple clinical milestones.

• Experienced team assembled since company inception last summer.

Pipeline and clinical development

• Budoprutug targets CD19, offering broad application in B-cell-mediated diseases.

• High-affinity, low-fucosylation design enables potent B-cell depletion and potential for subcutaneous administration.

• Three main indication categories: IgG4-mediated diseases (lead: primary membranous nephropathy), single-organ rare autoimmune diseases (lead: ITP), and complex systemic diseases (lead: SLE).

Clinical data and market opportunity

• Phase 1b in PMN showed high complete response rates and durable B-cell depletion with favorable safety.

• PMN affects 40,000 in the U.S., with 40% refractory to current therapies.

• ITP and SLE trials are being initiated, targeting high unmet need populations.

• SLE trial aims to replicate CAR-T-like efficacy with a monoclonal antibody.